Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Faeth Therapeutics, Inc. (FTH)

Faeth Therapeutics reports preliminary Phase 2 PIKTOR data in endometrial cancer

Neutral Impact 3 of 5 other

Faeth Therapeutics filed a November 9, 2026 corporate presentation with topline results from its single-arm Phase 2 PIK-201 trial of PIKTOR plus paclitaxel in advanced endometrial cancer. The filing says the results are preliminary and that PIKTOR is investigational and not approved, so the data does not yet establish a commercial outlook for shareholders.

Key points

  • Confirmed objective response rate of 33% (12 of 36 efficacy-evaluable patients), with a 10.30.26 efficacy data cut
  • Preliminary median progression-free survival of 7.4 months (95% CI 5.3, not reached) across 42 treated patients
  • 27 of 42 patients (64%) had a grade 3 or higher treatment-related adverse event, per the 10.23.26 safety data cut

The filing

CompanyFaeth Therapeutics, Inc. (FTH)
Form8-K, current report
Filed with the SECNov 9, 2026, 8:45 AM ET
Accession number0001193125-26-452755

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 9:25 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.